# A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

> **NCT02153476** · PHASE2 · COMPLETED · sponsor: **Allegro Ophthalmics, LLC** · enrollment: 45 (actual)

## Conditions studied

- Symptomatic Focal Vitreomacular Adhesion

## Interventions

- **DRUG:** 2.0mg of ALG-1001
- **DRUG:** Balanced Salt Solution

## Key facts

- **NCT ID:** NCT02153476
- **Lead sponsor:** Allegro Ophthalmics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02153476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02153476, "A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02153476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*